Hwail Pharmaceutical Co.Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.033x

Hwail Pharmaceutical Co.Ltd cash flow conversion efficiency. Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.82 Billion ≈ $4.62 Million USD) by net assets (₩207.86 Billion ≈ $140.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hwail Pharmaceutical Co.Ltd (2011–2024)

Cash flow conversion efficiency of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. This chart illustrates how Hwail Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Hwail Pharmaceutical Co.Ltd stock price today for real-time trading data and today's change.

Hwail Pharmaceutical Co.Ltd Cash Flow Conversion Ratio Explained

Hwail Pharmaceutical Co.Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hwail Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency. Also see Hwail Pharmaceutical Co.Ltd (061250) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Edda Wind ASA OL:EWIND	0.018x
ECARX Holdings Inc. Class A Ordinary shares NASDAQ:ECX	-0.145x
Wuhan Nusun Landscape Co Ltd SHE:300536	0.000x
Planet Technology TWO:6263	0.091x
CapMan Oyj B HE:CAPMAN	-0.087x
Drugs Made In America Acquisition Corp. Units NASDAQ:DMAAU	-0.001x
KG Mobility Corp. KO:003620	0.049x
WCM Global Growth Ltd AU:WQG	0.033x

Annual Cash Flow Conversion Efficiency for Hwail Pharmaceutical Co.Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. Review free cash flow generation of Hwail Pharmaceutical Co.Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩203.42 Billion ≈ $137.85 Million	₩11.63 Billion ≈ $7.88 Million	0.057x	+42.04%
2023-12-31	₩174.45 Billion ≈ $118.22 Million	₩7.02 Billion ≈ $4.76 Million	0.040x	+3126.94%
2022-12-31	₩175.57 Billion ≈ $118.98 Million	₩-233.56 Million ≈ $-158.28K	-0.001x	-101.20%
2021-12-31	₩181.66 Billion ≈ $123.11 Million	₩20.09 Billion ≈ $13.61 Million	0.111x	+8700.50%
2020-12-31	₩156.86 Billion ≈ $106.30 Million	₩-201.69 Million ≈ $-136.68K	-0.001x	-104.16%
2019-12-31	₩119.43 Billion ≈ $80.94 Million	₩3.69 Billion ≈ $2.50 Million	0.031x	-56.33%
2018-12-31	₩101.25 Billion ≈ $68.61 Million	₩7.17 Billion ≈ $4.86 Million	0.071x	-16.62%
2017-12-31	₩98.18 Billion ≈ $66.53 Million	₩8.34 Billion ≈ $5.65 Million	0.085x	-11.50%
2016-12-31	₩99.86 Billion ≈ $67.67 Million	₩9.58 Billion ≈ $6.49 Million	0.096x	+237.50%
2015-12-31	₩98.94 Billion ≈ $67.05 Million	₩-6.90 Billion ≈ $-4.68 Million	-0.070x	-123.28%
2014-12-31	₩89.07 Billion ≈ $60.36 Million	₩-2.78 Billion ≈ $-1.89 Million	-0.031x	-138.69%
2013-12-31	₩86.31 Billion ≈ $58.49 Million	₩6.97 Billion ≈ $4.72 Million	0.081x	+561.06%
2012-12-31	₩82.22 Billion ≈ $55.72 Million	₩1.00 Billion ≈ $680.89K	0.012x	-89.19%
2011-12-31	₩69.49 Billion ≈ $47.09 Million	₩7.86 Billion ≈ $5.32 Million	0.113x	--

About Hwail Pharmaceutical Co.Ltd

KQ:061250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$308.67 Million

₩455.48 Billion KRW

Market Cap Rank

#14355 Global

#441 in Korea

Share Price

₩5430.00

Change (1 day)

-1.81%

52-Week Range

₩918.00 - ₩9530.00

All Time High

₩9530.00